Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh, Ulrik Tarp, Natalia Manilo, Anne Gitte Rasmussen Loft, Annette Hansen, Annette Schlemmer, Victoria Fana, Hanne M. Lindegaard, Henrik Nordin, Claus Rasmussen, Leif Ejstrup, Dorte Vendelbo Jensen, Peter Mosborg Petersen, Merete Lund Hetland

123 Citations (Scopus)

Abstract

OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p
Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Volume72
Pages (from-to)1149-1155
ISSN0003-4967
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry'. Together they form a unique fingerprint.

Cite this